MedTrace Logo

Mechanism of Action of Ocrelizumab in Multiple Sclerosis

NCT03344094 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2025-02-21

Study results available
· View outcomes & findings →

Summary

Ocrelizumab is FDA approved for therapy of multiple sclerosis (MS). It depletes B cells and stops MS inflammation.

Conditions

Interventions

DRUG

ocrelizumab

FDA-approved MS drugs

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • anthony t reder, md · University of Chicago

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-02-23
Primary Completion
2019-04-10
Completion
2019-04-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03344094 on ClinicalTrials.gov